Market analysis
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an uncommon neurological immune system issue where myelin, a fundamental part of the nervous system is being attacked by the immune system of the body. There has been a spiraling ascent in the predominance of autoimmune disorders in the past which offers scope for the development of the global chronic inflammatory demyelinating polyneuropathy disease market. Different new medications have been propelled into the market after ongoing FDA endorsements which likewise supports the development of the global chronic inflammatory demyelinating polyneuropathy disease market. Different factors empowering the development of the market incorporate growing awareness about the disease and government attempts in the same issue. On the drawback, the mind-boggling expense of Intravenous immunoglobulin treatment and its side effects remains the major obstruction to the development of the market. The market is growing at a CAGR of 6.2% and is anticipated to reach USD 3907.17 Mn by the end of the forecast period 2018-2023.

Market Segmentation
Based on its treatment & diagnosis, the global chronic inflammatory demyelinating polyneuropathy disease market is segmented as Corticosteroids, Treatment Intravenous Immunoglobulin, Electrodiagnostic Testing, Physiotherapy, Spinal Fluid Analysis, Nerve Conduction, Plasmapheresis (plasma exchange), Diagnosis, EMG, Others. By end-user, the market is segmented as Specialty Neurological Clinics, Hospitals, Research & Academic Laboratories, Others. By route of administration, the market is again bifurcated into oral, intravenous and others.



Regional analysis
Geographically, the global chronic inflammatory demyelinating polyneuropathy disease market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major players
Kedrion S.p.A, Octapharma, Shire, Mitsubishi Tanabe Pharma Corporation, Momenta Pharmaceuticals, Grifols, Baxter, among others are some of the major players in the global chronic inflammatory demyelinating polyneuropathy disease market.